STOCK TITAN

SOPHiA GENETICS to Report Third Quarter 2021 Financial Results on November 10, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

BOSTON and LAUSANNE, Switzerland, Oct. 27, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the third quarter of 2021 before market open on Wednesday, November 10, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 2:30 p.m. Central European Time to discuss its results, business developments, and outlook.

Live audio of the webcast will be available on the “Investors” section of the company website at ir.sophiagenetics.com. An archived replay will be available on the company’s website following the event.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

Media Contact:
Eliza Bamonti
ebamonti@sophiagenetics.com

Investor Contact:
ir@sophiagenetics.com


SOPHiA Genetics SA

NASDAQ:SOPH

SOPH Rankings

SOPH Latest News

SOPH Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing

About SOPH

sophia genetics, world's largest clinical genomics community, brings together expertise in genetics, bioinformatics, machine learning and genomic privacy. based in switzerland, we are known for our high medical standards and swiss precision. sophia genetics offers health professionals who perform clinical genetic testing unparalleled bioinformatics analysis, quality assurance and secure banking of patient dna sequence data generated by ngs. the company helps clinical laboratories to reduce costs, overcome complexity, significantly improve the turnaround time for routine diagnosis and meet quality requirements related to the use of ngs in the clinic. our solution, the sophia ddm™ platform allows hospitals to better and faster diagnose patients using cutting edge ngs analytics algorithms and through knowledge sharing within the largest clinical genomics community in the world (+100 hospitals). the name « sophia » means wisdom in greek and it is the definition of our excellence based